BR112015012497B1 - Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial - Google Patents

Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial Download PDF

Info

Publication number
BR112015012497B1
BR112015012497B1 BR112015012497-6A BR112015012497A BR112015012497B1 BR 112015012497 B1 BR112015012497 B1 BR 112015012497B1 BR 112015012497 A BR112015012497 A BR 112015012497A BR 112015012497 B1 BR112015012497 B1 BR 112015012497B1
Authority
BR
Brazil
Prior art keywords
compound
combination
pharmaceutically acceptable
methyl
fluoro
Prior art date
Application number
BR112015012497-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015012497A2 (pt
BR112015012497A8 (pt
Inventor
Dale Porter
Caroline Emery
Lujian Tan
Padmaja Yerramilli- Rao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015012497A2 publication Critical patent/BR112015012497A2/pt
Publication of BR112015012497A8 publication Critical patent/BR112015012497A8/pt
Publication of BR112015012497B1 publication Critical patent/BR112015012497B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015012497-6A 2012-11-29 2013-11-26 Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial BR112015012497B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US61/731,174 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US61/731,555 2012-11-30
US201361755520P 2013-01-23 2013-01-23
US61/755,520 2013-01-23
PCT/US2013/071852 WO2014085381A1 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Publications (3)

Publication Number Publication Date
BR112015012497A2 BR112015012497A2 (pt) 2017-07-11
BR112015012497A8 BR112015012497A8 (pt) 2019-10-01
BR112015012497B1 true BR112015012497B1 (pt) 2022-05-17

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012497-6A BR112015012497B1 (pt) 2012-11-29 2013-11-26 Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial

Country Status (16)

Country Link
US (1) US9446043B2 (https=)
EP (1) EP2925366B1 (https=)
JP (1) JP6437444B2 (https=)
CN (1) CN104812415A (https=)
AU (1) AU2013352379B2 (https=)
BR (1) BR112015012497B1 (https=)
CA (1) CA2892578C (https=)
DK (1) DK2925366T3 (https=)
ES (1) ES2669248T3 (https=)
HU (1) HUE037618T2 (https=)
NZ (1) NZ708802A (https=)
PL (1) PL2925366T3 (https=)
RU (1) RU2674995C2 (https=)
TR (1) TR201806682T4 (https=)
UA (1) UA115250C2 (https=)
WO (1) WO2014085381A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
US20240207257A1 (en) * 2021-04-15 2024-06-27 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
US20260083731A1 (en) * 2022-08-26 2026-03-26 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor
GB202408599D0 (en) * 2024-06-14 2024-07-31 Vasopharma Ab Combination treatments
GB202408598D0 (en) * 2024-06-14 2024-07-31 Edvince Ab Combination treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
NO308798B1 (no) 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
YU49315B (sh) 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
AU2002221810B2 (en) * 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
AU2005252110B2 (en) 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
AU2006268908A1 (en) 2005-07-11 2007-01-18 Novartis Ag Indolylmaleimide derivatives

Also Published As

Publication number Publication date
HK1215789A1 (en) 2016-09-15
EP2925366A1 (en) 2015-10-07
UA115250C2 (uk) 2017-10-10
HUE037618T2 (hu) 2018-09-28
BR112015012497A2 (pt) 2017-07-11
BR112015012497A8 (pt) 2019-10-01
TR201806682T4 (tr) 2018-06-21
AU2013352379A1 (en) 2015-06-11
AU2013352379B2 (en) 2018-09-06
RU2015124954A (ru) 2017-01-11
RU2674995C2 (ru) 2018-12-14
JP6437444B2 (ja) 2018-12-12
EP2925366B1 (en) 2018-02-21
JP2016501222A (ja) 2016-01-18
CN104812415A (zh) 2015-07-29
NZ708802A (en) 2019-09-27
WO2014085381A1 (en) 2014-06-05
CA2892578C (en) 2021-01-12
CA2892578A1 (en) 2014-06-05
DK2925366T3 (en) 2018-06-06
US9446043B2 (en) 2016-09-20
PL2925366T3 (pl) 2018-08-31
US20150306101A1 (en) 2015-10-29
ES2669248T3 (es) 2018-05-24

Similar Documents

Publication Publication Date Title
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
AU2018262891A1 (en) Combination therapy
EP3086810A2 (en) Pharmaceutical combinations
ES2901712T3 (es) Combinación de un inhibidor de pi3k y un inhibidor de c-met.
CN104994850A (zh) 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
BR112015012497B1 (pt) Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
US20160129003A1 (en) Pharmaceutical Combinations
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
US20160120871A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
WO2014174478A1 (en) Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
HK1215789B (en) Pharmaceutical combinations
ES2963706T3 (es) Masitinib para el tratamiento del cáncer de próstata resistente a la castración
JP2009108058A (ja) 抗リンパ腫組成物および方法
WO2017013271A1 (en) Combination of an inhibitor of phosphatidylinositol 3-kinase delta and a bcl-2 inhibitor, uses and pharmaceutical compositions thereof
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2013, OBSERVADAS AS CONDICOES LEGAIS